GLP-1 receptor agonists have also been approved for the treatment of obesity, which broadens their application beyond diabetes management. The dose used for obesity treatment is often higher than that used for diabetes, raising questions about the dose-dependent toxicological implications. While the benefits in weight loss and metabolic health are evident, careful monitoring for any increased risk of adverse effects is warranted in this population.
